5 min
Christopher Bunick, MD, PhD - August 11, 2022 - The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis DermDocs
-
- Education
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression? As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their patients? Atopic dermatitis is stated to impact several areas of a patient’s life, including the quality. How can clinicians best address this issue from a patient-centered perspective? What key takeaways should clinicians consider when constructing a management plan for chronic illnesses such as moderate to severe atopic dermatitis?
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression? As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their patients? Atopic dermatitis is stated to impact several areas of a patient’s life, including the quality. How can clinicians best address this issue from a patient-centered perspective? What key takeaways should clinicians consider when constructing a management plan for chronic illnesses such as moderate to severe atopic dermatitis?
5 min